Takeda expanded Weave Bio's AI regulatory platform across 14 drug development programs.
Regulatory dossier preparation is a large administrative bottleneck. Weave Bio's platform drafts IND modules and handles health authority question intake and response workflows, with humans verifying and approving. The report cites nonclinical summary drafting down from about 100 hours to three (97%), a 60% shorter timeline, about 95% fidelity to source, and 68% average answer quality on 100+ questions.
Weave Bio is an AI-native regulatory automation platform, used by pharma, biotech and CROs to draft IND and NDA content and respond to health authority questions
This sits in the Scale & Govern stage of the AI use-case lifecycle: Named examples from the tools pharma teams use to monitor, govern and keep validating an AI system once it is already live in production.
Published by Weave Bio on its own site — read the original case study on hlth.com ↗
Related use cases
- 01Trace Biosciences prepared its first IND submission using Weave Bio's Submission Builder.
- 02Parexel co-designed NDA templates with Weave Bio and reports 60% faster authoring.
- 03How (And Why) AdeptID Achieved EU AI Act Compliance for Talent Matching
- 04Establishing Lifecycle AI Risk Management for Defense Operations
- 05Unifying AI Governance Across Global Operations at Scale
- 06Embedding & Automating AI Governance in Enterprise Workflows